Downstream Processing

Aug 01, 2016
By BioPharm International Editors
An MIT-developed system uses microbes for manufacturing small amounts of vaccines and other therapies.
Jul 27, 2016
By BioPharm International Editors
The affinity purification company will set up shop at the former Merck & Co./GlycoFi facility in the Dartmouth Regional Technology Center in New Hampshire.
Jul 19, 2016
By BioPharm International Editors
FDA issued a warning letter to the Worthing, UK facility for cross contamination and microbial contamination cGMP violations.
Jul 01, 2016
BioPharm International
CPhI Pharma Awards seek nominations for excellence in biopharma development and manufacturing.
Jul 01, 2016
BioPharm International
Pressures to accelerate current and next-gen therapies are challenging traditional microbiological testing methods.
Jun 28, 2016
By BioPharm International Editors
MilliporeSigma and the International Vaccine Institute in Seoul, South Korea aim to develop more robust, scalable vaccine manufacturing processes.
Jun 15, 2016
BioPharm International
By BioPharm International Editors
Technology advances enable contract service providers to keep pace with the demands of existing and emerging biologic-based therapies.
Jun 01, 2016
BioPharm International
Advances in cell line engineering, process optimization, and in-vitro glycosylation are making a difference.
May 04, 2016
By BioPharm International Editors
MilliporeSigma expands its Carlsbad, California-based GMP capacity for viral and gene-therapy products by nearly 90%.
May 01, 2016
BioPharm International
Testing product and process intermediates alone is helpful, but does not provide a complete solution to viral safety. This article proposes integrated solutions for systemic and proactive viral risk mitigation.
native1_300x100
lorem ipsum